March 19, 2019
Vol. 16 No. 53
View Archived Issues
Sign Up Now
Sharpless has advocated for increased modernization of clinical trials.
Read More
Agency prioritized review to stave off shortages.
Read More
J&J labeled “kingpin” of opioid crisis.
Read More
Evidence “not strong enough” to justify expense, regulator says.
Read More
The series of draft guidances encourages a broadening of eligibility criteria.
Read More
